KULA-101

N/A

Report date: 2022/09/09 14:09:28
NME

Base Information

Drug NameKULA-101
Drug Alias NameKULA101
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCluster of differentiation 8 inhibitorsCytotoxic T lymphocytes stimulantsProgrammed cell death protein 1 blockers +[9] 
TargetsTumor necrosis factor receptor superfamily member 5Cytotoxic T-Lymphocyte-Associated Antigen 4Cluster of differentiation 8 +[6] 
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesPartikula LLC
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesPartikula LLC
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A